drugset / Trial / NCT00529646

Single-Dose Safety Study of APD791 in Healthy Volunteers

NCT00529646

Phase 1 Completed 90 enrolled Arena Pharmaceuticals
RandomizedQuadruple-blind

Summary

The APD791-001 study is designed primarily to evaluate the safety and tolerability of APD791 when administered as a single oral dose to healthy adult subjects.

Timeline

Start
2007-07
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Temanogrel Small molecule Oral

Indications

No indication recorded.